Wall Street brokerages forecast that MorphoSys AG Unsponsored ADR (NYSE:MOR) will report sales of $12.41 million for the current quarter, according to Zacks. Two analysts have provided estimates for MorphoSys’ earnings, with estimates ranging from $12.21 million to $12.61 million. MorphoSys reported sales of $11.98 million during the same quarter last year, which indicates a positive year-over-year growth rate of 3.6%. The firm is expected to report its next quarterly earnings results on Wednesday, March 11th.

According to Zacks, analysts expect that MorphoSys will report full-year sales of $80.28 million for the current year, with estimates ranging from $78.81 million to $82.30 million. For the next financial year, analysts anticipate that the company will post sales of $161.38 million, with estimates ranging from $98.17 million to $242.77 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for MorphoSys.

Separately, Svb Leerink restated an “outperform” rating on shares of MorphoSys in a research report on Tuesday, January 14th.

Shares of MorphoSys stock traded down $0.72 on Friday, hitting $30.76. 93,438 shares of the company’s stock traded hands, compared to its average volume of 116,426. MorphoSys has a one year low of $22.46 and a one year high of $37.96. The company has a fifty day moving average of $33.54 and a two-hundred day moving average of $30.59.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: How does a dividend reinvestment plan work?

Get a free copy of the Zacks research report on MorphoSys (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.